General
Preferred name
SNS-032
Synonyms
BMS-387032 ()
SNS032 ()
BMS387032, cmpd 21 ()
SNS 032 ()
SNS-032 (BMS-387032) ()
BMS-3870032 ()
Sns 032 ()
BMS387032 ()
P&D ID
PD003662
CAS
345627-80-7
Tags
available
molecular glue
drug candidate
obsolete probe
Drug indication
Chronic lymphocytic leukemia
Cancer
Solid tumour/cancer
Drug Status
investigational
Max Phase
1.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
BMS-387032 was originally reported as a potent and selective inhibitor of cyclin-dependent kinase 2 . It has subsequently been discovered to potently inhibit CDK7 and CDK9 .
(GtoPdb)
DESCRIPTION
SNS-032 (BMS-387032) is a potent and selective inhibitor of CDK2, CDK7, and CDK9 with IC50s of 38 nM, 62 nM and 4 nM, respectively. SNS-032 has antitumor effect[1].
PRICE
52
DESCRIPTION
inhibitor of cyclin-dependent kinases
(Informer Set)
DESCRIPTION
NAMPT activator; also proneurogenic and neuroprotective
(Tocris Bioactive Compound Library)
DESCRIPTION
SNS-032, also known as BMS-387032, is a 2-aminothiazole-derived, small-molecule cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. CDK inhibitor SNS-032 selectively binds to CDKs 2, 7, and 9, preventing their phosphorylation and activation; inhibition of CDK activity may result in cell cycle arrest, the induction of apoptosis and decreased tumor cell proliferation in susceptible tumor cell populations. This agent has been shown to sensitize radioresistant tumor cells to ionizing radiation.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
SNS-032 is a potent and selective inhibitor of CDK2, CDK7, and CDK9 with antitumor effect.
(Enamine Bioactive Compounds)
DESCRIPTION
SNS-032 (BMS-387032) is a selective inhibitor of CDK2 (IC50: 48 nM), exhibiting 10- and 20-fold selectivity over CDK1 and CDK4, respectively. It is also sensitive to CDK7 (IC50: 62 nM) and CDK9 (IC50: 4 nM), with no effect on CDK6.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
7
Organisms
1
Compound Sets
25
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
CDK inhibitor database (CDKiDB)
ChEMBL Drugs
Clinical kinase drugs
Drug Repurposing Hub
DrugBank
Enamine Bioactive Compounds
EUbOPEN Chemogenomics Library
Guide to Pharmacology
Informer Set
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
MolGlueDB
Novartis Chemogenetic Library (NIBR MoA Box)
Obsolete Compounds
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
32
Molecular Weight
380.13
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
2
cLogP
3.66
TPSA
80.05
Fraction CSP3
0.59
Chiral centers
0.0
Largest ring
6.0
QED
0.77
Structural alerts
1
historic compounds (Chemical Probes.org)
Obsolete
Related compounds
Custom attributes
(extracted from source data)
Target
CDK16
CDK17
CDK2
CDK7
CDK9
CDKL5
Apoptosis
CDK
CDK2/CyclinA
CDK2/CyclinE
CDK7/CyclinH
CDK9/CyclinT
GSK-3α
CDK2, CDK7, CDK9
CDK2 inhibitor
Apoptosis related,CDK
Compound status
clinical
Targets
CDK2,CDK7,CDK9
Primary Target
Cyclin-Dependent Protein Kinases
MOA
Inhibitor
CDK7 Inhibitors
CDK2/Cyclin E Inhibitors
CDK9 Inhibitors
CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor
Member status
member
Therapeutic Class
Anticancer Agents
Pathway
Cell Cycle/DNA Damage
Cell Cycle/Checkpoint
PI3K/Akt/mTOR signaling
Stem Cells
Recommended Cell Concentration
None
Source data
